zheniya.online


PLX STOCK FORECAST 2021

What is the PE ratio for Protalix Biotherapeutics Inc (PLX)? The price to earnings ratio for PLX stock is as of 8/16/ What is the current PE ratio. PLX - Protalix BioTherapeutics, Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NYSEAM) , we no longer show owners that have not. Stock analysis for Protalix BioTherapeutics Inc (PLX:NYSEAmerican) including stock price, stock chart, company news, key statistics, fundamentals and. Losses were -$ million, % less than in According to one analyst, the rating for PLX stock is "Strong Buy" and the month stock price forecast. Research Protalix BioTherapeutics' (TASE:PLX) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance.

Daily market news in bullet point format. Subscribe. © Stock Analysis. All rights reserved. Find the latest PROTALIX BIOTHERAPEUTICS, INC. (PLX) discussion and analysis from iHub's community of investors. The average one-year price target for Protalix BioTherapeutics, Inc. is $ The forecasts range from a low of $ to a high of $ The PLX ticked the lowest adjusted close price of $ on The corresponding close (unadjusted stock price) was $ Note: The lowest. Get Protalix Biotherapeutics Inc (zheniya.online) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments. (PLX) stock price quote, stock graph, news & analysis Investors did not like the company's latest regulatory update. Prosper Junior Bakiny | Apr 28, (DE) future price: according to them, PLX price has a max estimate of USD and a min estimate of USD. Watch PLX chart and read a more detailed. In connection with the offering, we issued 8,, shares of our common stock at a purchase price per share of $ On June 7, , we issued , Protalix BioTherapeutics, Inc.: Forcasts, revenue, earnings, analysts expectations, ratios for Protalix BioTherapeutics, Inc. Stock | PLX | USA Protalix BioTherapeutics has generated $ earnings per share over the last year ($ diluted earnings per share) and currently has a price-to-earnings.

Get Protalix Biotherapeutics Inc (PLX.Z) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments. Earnings are forecast to grow % per year · Trading at good value compared to peers and industry · Shareholders have been diluted in the past year · Does not. The 2 analysts offering price forecasts for Protalix BioTherapeutics have a median target of , with a high estimate of and a low estimate of Stock analysis for Pluxee NV (PLX:EN Paris) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Our Protalix Biotherapeutics Inc stock forecast data is based on consensus analyst prediction, covering public companies earnings per share and revenue. Please refer to the Stock Price Adjustment Guide for more information on our historical prices. Compare PLX With Other Stocks , , $ Stock Price Targets ; High, $ ; Median, $ ; Low, $ ; Average, $ ; Current Price, $ Historical daily share price chart and data for Protalix BioTherapeutics since adjusted for splits and dividends. The latest closing stock price for. Protalix BioTherapeutics, Inc.'s stock symbol is PLX and currently trades under NYSE. It's current price per share is approximately $ What is Protalix.

Protalix BioTherapeutics stock forecast. PLX Stock Price Protalix BioTherapeutics (PLX) CEO, Dror Bashan on Q4 Results - Earnings Call Transcript. According to our current PLX stock forecast, the value of Protalix Biotherapeutics shares will rise by % and reach $ per share by September Forecast Spread, 38,4 37,6 %, 47,6 45,1 %, 65,5 64,0 %, 53,7, Annual profits - Rate of surprise. Stock Market · Equities · PLX Stock; Calendar. 3 Is Protalix Biotherapeutics (PLX) Stock Rising For Recent 36 Months? ; , , ( %) ; , , ( %) ; , ( %). Overall Rise = (Stock Price of - Stock Price of ) = ( - ) = Rise% = ((Overall Rise/Stock Price of

Missing Stimulus Check Phone Number | 50 Gig Internet

19 20 21 22 23


Copyright 2016-2024 Privice Policy Contacts